Compugen Ltd. (NASDAQ:CGEN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Compugen Ltd. (NASDAQ:CGEN) have been assigned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $5.00.

A number of analysts have weighed in on the company. Lake Street Capital assumed coverage on Compugen in a report on Tuesday, April 7th. They set a “buy” rating and a $6.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compugen in a report on Monday, April 20th. Truist Financial raised Compugen to a “strong-buy” rating in a research report on Wednesday, March 25th. Leerink Partners decreased their price objective on Compugen from $13.00 to $5.00 and set an “outperform” rating for the company in a research note on Thursday, May 21st. Finally, Wall Street Zen downgraded Compugen from a “buy” rating to a “hold” rating in a research report on Saturday, May 23rd.

Institutional Trading of Compugen

Several hedge funds have recently modified their holdings of CGEN. Security National Bank of Sioux City Iowa IA purchased a new position in shares of Compugen in the 4th quarter worth approximately $38,000. Marshall Wace LLP raised its stake in shares of Compugen by 135.7% during the 4th quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 61,202 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in Compugen during the fourth quarter valued at approximately $84,000. Raymond James Financial Inc. lifted its position in Compugen by 51.0% during the third quarter. Raymond James Financial Inc. now owns 101,256 shares of the biotechnology company’s stock valued at $149,000 after acquiring an additional 34,215 shares during the last quarter. Finally, Two Sigma Investments LP boosted its stake in Compugen by 10.6% in the third quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock valued at $291,000 after acquiring an additional 18,929 shares in the last quarter. 12.22% of the stock is owned by hedge funds and other institutional investors.

Compugen Stock Performance

Shares of CGEN opened at $2.30 on Friday. The company has a 50 day moving average price of $2.39 and a 200-day moving average price of $2.20. Compugen has a fifty-two week low of $1.29 and a fifty-two week high of $3.23. The stock has a market capitalization of $217.46 million, a PE ratio of 6.22 and a beta of 2.76.

Compugen (NASDAQ:CGEN) last released its quarterly earnings data on Monday, May 18th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The business had revenue of $2.18 million for the quarter, compared to the consensus estimate of $1.57 million. Compugen had a net margin of 47.97% and a return on equity of 47.72%. Equities research analysts forecast that Compugen will post -0.28 EPS for the current year.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.